SecBot SecBot

PLSE

PULSE BIOSCIENCES, INC.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001625101 Biotech & Drug Discovery
$52.66 −0.36 (−0.68%)
Oct 26 4:00 PM ET · prev $53.02
Market cap
$3.8B
Mid cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$59.00
+12% · range $55.00–73.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.29
1 year
+200.9%
from $17.50 · Oct 27
30 days
+0.6%
from $52.32
52-week range
$12.66–55.20
−5% from high · low Nov 20
Avg volume 20D
416.0K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$10.6M
3 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
18
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 2 bearish · 3 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 6/6 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Pulse Biosciences announced it has achieved its enrollment target of 164 evaluable patients in the…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $13.5M at an average $19.87. 1 insider sold $2.9M. Price is 165% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 16 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.285 → −$0.287 over 90 days. 0 up, 1 down in 30 days.

  • TrendRANGE

    4% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BANK OF AMERICA CORP /DE/ADD1,446,611$40.1M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED748,638$20.8M
BALYASNY ASSET MANAGEMENT L.P.DOUBLED718,103$19.9M
CITADEL ADVISORS LLCDOUBLED626,514$17.4M
UBS Group AGDOUBLED275,669$7.6M
Nuveen, LLCDOUBLED101,683$2.8M
D. E. Shaw & Co., Inc.DOUBLED81,818$2.3M
MORGAN STANLEYTRIM31,995$887.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy7Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +12%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 13, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Oct 6, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Sep 23, 2026BTIG
INITIATE
INITIATEBuy
Sep 9, 2026Freedom Capital Markets
INITIATE
INITIATEBuy
Aug 17, 2026Needham
INITIATE
INITIATEBuy
Aug 10, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$13.5M
bought · 3 insiders
$2.9M
sold · 1 insider
+165.1%
vs their $19.87 cost
DateInsiderTypeValue
Sep 1, 2026
Teplitsky Liane Rae
Chief Operating Officer
BUY$50.0K
Aug 31, 2026
Teplitsky Liane Rae
Chief Operating Officer
BUY$50.0K
Aug 28, 2026
Teplitsky Liane Rae
Chief Operating Officer
BUY$50.0K
Aug 26, 2026
Teplitsky Liane Rae
Chief Operating Officer
BUY$50.0K
Aug 8, 2026
Teplitsky Liane Rae
Chief Operating Officer
AWARD200,000 sh
Aug 8, 2026
Teplitsky Liane Rae
Chief Operating Officer
AWARD700,000 sh
Jun 11, 2026
Sainz Maria
Director
AWARD30,000 sh
Jun 11, 2026
Soni Manmeet Singh
Director
AWARD30,000 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.29
EPS estimate, this quarter
−1%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.29-$0.30–-$0.28+0.9%$521.7K
Next Q-$0.30-$0.32–-$0.29+1.1%$695.0K
Current FY-$1.11-$1.13–-$1.09+0.5%$2.0M
Next FY-$1.17-$1.26–-$1.05-1.4%$5.7M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for…
8-K — Impact 4/10
Oct 7, 2026 SEC
Pulse Biosciences announced it has achieved its enrollment target of 164 evaluable patients in the NANOPULSE-AF IDE…
8-K — Impact 6/10
Sep 15, 2026 SEC
Pulse Biosciences announced completion of patient enrollment (100 patients, doubled from original 50) in its…
8-K — Impact 6/10
Sep 1, 2026 Insider
Teplitsky Liane Rae bought 1,001 shares
Chief Operating Officer @ $49.95 ($50.0K)
Aug 31, 2026 Insider
Teplitsky Liane Rae bought 1,024 shares
Chief Operating Officer @ $48.80 ($50.0K)
Aug 28, 2026 Insider
Teplitsky Liane Rae bought 1,034 shares
Chief Operating Officer @ $48.35 ($50.0K)
Aug 6, 2026 Earnings calendar
PLSE Q2 2026 Earnings Scheduled — 2026-08-06
Jun 30, 2026 Inst.
BANK OF AMERICA CORP — ADD
1,446,611 shares ($40.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
PLSE Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Aug 6, 2026
Earnings date
PLSE Q2 2026 Earnings Scheduled — 2026-08-06
May 7, 2026
Earnings date
PLSE Q1 2026 Earnings Scheduled — 2026-05-07
Apr 13, 2026
Short interest
FTD: PLSE — 27,116 shares ($0.5M) failed to deliver
Settlement: 20260413, Price: $18.67, FTD Value: $506,255.72, PULSE BIOSCIENCES INC COM (DE)
Apr 2, 2026
Short interest
FTD: PLSE — 23,040 shares ($0.5M) failed to deliver
Settlement: 20260402, Price: $23.03, FTD Value: $530,611.2, PULSE BIOSCIENCES INC COM (DE)
Mar 16, 2026
Short interest
FTD: PLSE — 47,748 shares ($1.0M) failed to deliver
Settlement: 20260316, Price: $21.57, FTD Value: $1,029,924.36, PULSE BIOSCIENCES INC COM (DE)

SecBot reports

18 filings · 10 bullish · 2 bearish · 1 mixed · 5 neutral
All PLSE filing & press-release reports (18)